What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

DNA Damage and Cancer: Mechanisms and Implications

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to DNA Damage and Cancer

What is DNA damage?

DNA damage refers to any chemical or physical alteration to the DNA molecule that deviates from its canonical structure. This includes modifications to individual bases, breaks in the sugar-phosphate backbone, crosslinks between bases, or the incorporation of incorrect nucleotides during replication. DNA damage is distinct from mutation: damage is a chemical alteration to the DNA that can often be repaired, whereas a mutation is a heritable change in the nucleotide sequence that persists after repair has failed or been bypassed.

The human genome sustains tens of thousands of damaging events per cell per day. These lesions arise from both normal cellular metabolism and environmental exposures. If left unrepaired, damage can block replication or transcription, trigger cell death, or—critically—become fixed as mutations. It is this last outcome that links DNA damage to cancer.

The connection between DNA damage and cancer is not merely correlative; it is mechanistic. Cancer is fundamentally a disease of the genome, characterized by the accumulation of mutations that confer selective growth advantages. Every cancer cell carries somatic mutations in genes that regulate cell proliferation, apoptosis, or DNA repair itself. The proximate cause of these mutations is DNA damage that escaped repair or was erroneously processed.

How DNA damage leads to mutations

The pathway from DNA damage to mutation is not direct. When a DNA lesion escapes repair, it encounters the replication machinery. Most DNA polymerases cannot accommodate damaged bases in their active sites and stall when they encounter them. This stall is itself dangerous: a stalled replication fork can collapse, generating double-strand breaks. Alternatively, the cell may activate translesion synthesis (TLS), a process in which specialized, error-prone polymerases replicate past the lesion. These TLS polymerases have relaxed active sites that can accommodate damaged bases, but they have no proofreading activity and often insert incorrect nucleotides opposite the lesion.

Consider the example of 8-oxoguanine, a common oxidative lesion. If unrepaired, 8-oxoguanine can pair with adenine rather than cytosine during replication. After a second round of replication, the adenine is paired with thymine, resulting in a G:C to T:A transversion. This single base substitution can activate an oncogene or inactivate a tumor suppressor if it occurs in a critical region. The DNA Damage Response normally prevents this outcome by arresting the cell cycle and recruiting repair factors, but when the response is overwhelmed or itself defective, mutagenesis proceeds.

Types of DNA Damage

DNA damage is broadly classified by its origin (endogenous vs. exogenous) and by its chemical nature. Understanding the types of damage is essential because each type is repaired by a specific pathway, and defects in these pathways predispose to distinct cancer spectra.

Endogenous damage

Endogenous damage arises from normal cellular processes. The most significant source is reactive oxygen species (ROS), produced as byproducts of mitochondrial oxidative phosphorylation. ROS such as hydroxyl radical (•OH), superoxide (O₂•⁻), and hydrogen peroxide (H₂O₂) attack DNA bases and the deoxyribose backbone. The hydroxyl radical is the most reactive and can abstract hydrogen atoms from deoxyribose, leading to single-strand breaks. It also adds to double bonds in bases, generating lesions like 8-oxoguanine, thymine glycol, and formamidopyrimidines.

Hydrolysis is a second major endogenous source. Spontaneous depurination—the loss of adenine or guanine bases—occurs at a rate of approximately 10,000 events per cell per day. The resulting apurinic (AP) sites are non-coding lesions that block polymerases. Deamination of cytosine to uracil occurs at a lower frequency but is mutagenic because uracil pairs with adenine during replication, causing C to T transitions. Methylation by S-adenosylmethionine, the universal methyl donor, can generate O⁶-methylguanine, a highly mutagenic lesion that mispairs with thymine.

Replication errors themselves constitute a form of endogenous damage. Despite the high fidelity of replicative polymerases (error rates of approximately 10⁻⁵ to 10⁻⁶), the sheer scale of genome duplication—3 billion base pairs per cell division—means that thousands of misincorporated nucleotides occur per cycle. Most are corrected by proofreading, and the remainder by mismatch repair, but those that escape both become mutations.

Exogenous damage

Exogenous damage comes from environmental sources. Ultraviolet (UV) radiation from sunlight induces covalent crosslinks between adjacent pyrimidines, forming cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts. These lesions distort the DNA helix and block replication. UV exposure is the primary cause of skin cancers, including basal cell carcinoma, squamous cell carcinoma, and melanoma.

Ionizing radiation (X-rays, gamma rays, and radioactive decay) deposits energy that can directly break the DNA backbone or generate ROS that attack DNA indirectly. The most dangerous lesions are double-strand breaks (DSBs), in which both strands are severed. A single unrepaired DSB can be lethal, and misrepaired DSBs cause chromosomal rearrangements.

Chemical carcinogens are diverse. Polycyclic aromatic hydrocarbons (PAHs) from tobacco smoke and grilled meats are metabolically activated to reactive epoxides that form bulky adducts on guanine. Aflatoxin B1, produced by Aspergillus fungi contaminating stored grains, is activated to aflatoxin-8,9-epoxide, which forms an adduct at the N⁷ position of guanine and causes G to T transversions—the hallmark mutation in hepatocellular carcinoma associated with aflatoxin exposure. Alkylating agents, including chemotherapeutic drugs like temozolomide, add alkyl groups to bases, producing lesions such as O⁶-methylguanine and N⁷-methylguanine. Crosslinking agents like cisplatin form intrastrand and interstrand crosslinks that block both replication and transcription.

The Diagram of DNA Damage illustrates how these diverse lesions differ in their structure and severity, which in turn determines which repair pathway is engaged.

DNA Repair Mechanisms

Cells possess multiple, partially overlapping DNA repair pathways. Each pathway is specialized for a class of lesions, and together they maintain genomic integrity. The critical role of these pathways in cancer prevention is underscored by the fact that inherited defects in nearly every repair pathway predispose to cancer.

Base excision repair

Base excision repair (BER) handles small, non-helix-distorting base lesions, including oxidized bases, alkylated bases, and AP sites. The pathway is initiated by a DNA glycosylase that recognizes the damaged base and cleaves the N-glycosidic bond, releasing the base and leaving an AP site. There are multiple glycosylases, each with substrate specificity: OGG1 removes 8-oxoguanine, UNG removes uracil, and MPG removes alkylated purines.

The resulting AP site is processed by AP endonuclease 1 (APE1), which nicks the backbone 5′ to the AP site. DNA polymerase β then fills the single-nucleotide gap, and DNA ligase III (in complex with XRCC1) seals the nick. In short-patch BER, a single nucleotide is replaced. In long-patch BER, used when the 5′ end is blocked, 2–10 nucleotides are replaced, and the flap is cleaved by FEN1. The entire process requires no more than five enzymes and can be reconstituted in vitro with purified components.

Nucleotide excision repair

Nucleotide excision repair (NER) removes bulky, helix-distorting lesions, including UV-induced photoproducts, PAH adducts, and intrastrand crosslinks. NER exists in two subpathways: global genomic NER (GG-NER), which surveys the entire genome, and transcription-coupled NER (TC-NER), which operates on the transcribed strand of active genes.

In GG-NER, the XPC-RAD23B complex recognizes the helical distortion. In TC-NER, a stalled RNA polymerase II serves as the recognition signal, recruiting CSA and CSB. Both pathways converge on the same core machinery: TFIIH unwinds the DNA around the lesion using its XPB and XPD helicases, XPA verifies the damage, and the endonucleases XPG (3′ cut) and ERCC1-XPF (5′ cut) excise a 24–32 nucleotide oligonucleotide containing the lesion. The resulting gap is filled by DNA polymerase δ or ε, and sealed by DNA ligase I. Defects in NER cause xeroderma pigmentosum, a syndrome characterized by a >1,000-fold increased risk of UV-induced skin cancers.

Mismatch repair

Mismatch repair (MMR) corrects replication errors—base-base mismatches and small insertion-deletion loops that escape polymerase proofreading. The pathway is initiated by the MutS homologs: MSH2-MSH6 (MutSα) recognizes base mismatches and small loops, while MSH2-MSH3 (MutSβ) recognizes larger loops. After binding, the MutL homologs (MLH1-PMS2, MutLα) are recruited, and the complex activates the endonuclease activity of PMS2, introducing nicks that direct excision.

The excision step removes a tract of DNA containing the mismatch, extending from the nick to beyond the error. EXO1 performs the resection, and the single-strand binding protein RPA protects the exposed template. DNA polymerase δ resynthesizes the strand, and DNA ligase I seals the nick. Because MMR must distinguish the newly synthesized strand from the template, it relies on the transient presence of nicks in the nascent strand—a feature that is lost after Okazaki fragment processing is complete.

Hereditary non-polyposis colorectal cancer (Lynch syndrome) is caused by germline mutations in MLH1, MSH2, MSH6, or PMS2. Tumors from these patients exhibit microsatellite instability, a hallmark of MMR deficiency, because repetitive sequences are particularly prone to slippage errors that MMR would normally correct.

Double-strand break repair

Double-strand breaks (DSBs) are the most dangerous lesions. They are repaired by two principal pathways: non-homologous end joining (NHEJ) and homologous recombination (HR).

NHEJ is active throughout the cell cycle and directly ligates the two broken ends. The Ku70/Ku80 heterodimer binds the break, recruiting DNA-PKcs. The Artemis nuclease trims damaged ends, and polymerases μ and λ fill in short gaps. Finally, DNA ligase IV, in complex with XRCC4 and XLF, seals the break. NHEJ is error-prone because it may delete or insert nucleotides at the junction, but it is essential for repairing breaks that occur in G1 phase when no sister chromatid is available.

HR is restricted to S and G2 phases, when a sister chromatid is present. The MRN complex (MRE11-RAD50-NBS1) and CtIP initiate 5′ end resection, generating single-stranded DNA (ssDNA) overhangs. RPA coats the ssDNA, then is replaced by RAD51 with the help of BRCA2. The RAD51-ssDNA filament invades the homologous duplex, forming a displacement loop. DNA synthesis extends the invading strand, and the resulting structures are resolved by helicases and nucleases to yield intact chromosomes. HR is error-free, but it requires the homologous template and is therefore unavailable in G1.

Defects in HR, particularly in BRCA1 and BRCA2, cause hereditary breast and ovarian cancer. These tumors are exquisitely sensitive to PARP inhibitors, which exploit the synthetic lethality of combining HR deficiency with inhibition of single-strand break repair. The DNA Damage Response coordinates these repair pathways with cell cycle checkpoints, ensuring that repair occurs before replication or division.

Consequences of Unrepaired DNA Damage

When repair fails, the consequences depend on the type of lesion, its location, and the cell cycle phase in which it is encountered. The ultimate outcome is mutation, chromosomal aberration, or cell death. In the context of cancer, the critical events are those that alter the function of genes controlling proliferation, apoptosis, or genome stability.

Point mutations and frameshifts

Point mutations are single base substitutions. Transitions (purine to purine or pyrimidine to pyrimidine) and transversions (purine to pyrimidine or vice versa) arise from different lesions. Deamination of 5-methylcytosine produces thymine, causing C to T transitions at CpG dinucleotides—the most common mutation in the human genome. Oxidative damage produces G to T transversions via 8-oxoguanine. UV damage produces C to T transitions at dipyrimidine sites, the signature of sunlight exposure.

Frameshift mutations—insertions or deletions of nucleotides not in multiples of three—arise from replication slippage at repetitive sequences. When a polymerase dissociates and reassociates, the nascent and template strands can misalign, causing the daughter strand to be longer or shorter. MMR normally corrects these errors, but in MMR-deficient cells, frameshifts accumulate at microsatellites. If a frameshift occurs in a tumor suppressor gene like TGFBR2 or BAX, it can inactivate the gene and promote tumor progression.

The functional impact of a point mutation depends on its location. A missense mutation changes one amino acid; a nonsense mutation introduces a premature stop codon; a silent mutation changes the codon but not the amino acid. In oncogenes, gain-of-function mutations typically cluster in specific hotspots. For example, KRAS mutations at codons 12, 13, and 61 lock the protein in its active GTP-bound state, driving constitutive proliferation. In tumor suppressors, loss-of-function mutations are distributed throughout the gene, and both alleles must be inactivated—the "two-hit" hypothesis.

Chromosomal aberrations

Chromosomal aberrations arise primarily from misrepaired DSBs. If two DSBs occur on different chromosomes and are joined by NHEJ, the result is a translocation. The classic example is the Philadelphia chromosome, a t(9;22) translocation that fuses BCR and ABL1, creating a constitutively active tyrosine kinase that drives chronic myeloid leukemia. Translocations can also create oncogenic fusion proteins, as in the t(8;14) translocation of Burkitt lymphoma that places MYC under the control of the immunoglobulin heavy chain enhancer.

Deletions and amplifications are copy number alterations that can inactivate tumor suppressors or amplify oncogenes. Loss of heterozygosity (LOH) occurs when one allele is deleted and the remaining allele carries a mutation, eliminating all functional copies of a tumor suppressor. Gene amplification, seen in ERBB2 (HER2) in breast cancer, increases oncogene dosage.

Genomic instability—an increased rate of mutation and chromosomal change—is a hallmark of cancer. It can result from defects in DNA repair, cell cycle checkpoints, or telomere maintenance. Telomere shortening, discussed in Telomerase Cause Cancer, leads to end-to-end chromosome fusions and breakage-fusion-bridge cycles, generating massive chromosomal rearrangements. The Effects of DNA Damage thus extend far beyond single genes, reshaping entire genomes.

Evidence Linking DNA Damage to Cancer

The assertion that DNA damage causes cancer rests on multiple independent lines of evidence. No single observation proves causation, but the convergence of epidemiological, genetic, and experimental data is compelling.

Cancer-prone syndromes

Inherited defects in DNA repair genes cause syndromes with dramatically elevated cancer risk. Xeroderma pigmentosum, caused by mutations in NER genes (XPA through XPG, ERCC1), confers a >1,000-fold increased risk of skin cancer. Ataxia-telangiectasia, caused by mutations in ATM (a key kinase in the DNA damage response), predisposes to lymphoid malignancies. Fanconi anemia, caused by mutations in any of 22 FANC genes involved in interstrand crosslink repair, causes bone marrow failure and acute myeloid leukemia. Lynch syndrome, from MMR defects, causes colorectal and endometrial cancer.

These syndromes demonstrate that when specific repair pathways are disabled, the corresponding lesions persist, mutations accumulate, and cancer follows. The tissue specificity of each syndrome reflects the types of damage that tissue experiences and the repair pathway that is compromised.

Carcinogen studies

Epidemiological studies of carcinogen exposure provide direct evidence that DNA-damaging agents cause cancer in humans. Tobacco smoke, which contains PAHs and nitrosamines, causes lung cancer with a dose-response relationship: the more cigarettes smoked, the higher the risk. The mutational signature of tobacco smoke—G to T transversions—is enriched in lung cancers from smokers. UV exposure causes skin cancer, with risk correlating with cumulative sun exposure and the presence of CPD signature mutations. Aflatoxin B1 exposure causes hepatocellular carcinoma, with the characteristic G to T transversion at codon 249 of TP53.

Animal models

Experimental animal models allow causal testing. Treating mice with carcinogens such as DMBA (7,12-dimethylbenz[a]anthracene) or ionizing radiation induces tumors with defined mutational spectra. Knockout mice lacking repair genes—Msh2⁻/⁻, Xpa⁻/⁻, Brca1⁻/⁻—develop tumors spontaneously or after carcinogen exposure. These models confirm that DNA damage is sufficient to cause cancer and that repair defects accelerate the process.

Methods to Study DNA Damage and Cancer

Studying DNA damage requires methods to detect lesions, quantify repair, and measure mutagenic outcomes. Several techniques are standard in the field.

Comet assay

The comet assay (single-cell gel electrophoresis) measures DNA strand breaks in individual cells. Cells are embedded in agarose on a microscope slide, lysed to remove membranes and proteins, and subjected to electrophoresis under alkaline conditions. DNA fragments migrate toward the anode, forming a "comet tail" whose length and intensity are proportional to the number of breaks. The assay can detect single-strand breaks, DSBs, and alkali-labile sites. It is simple, sensitive, and requires only a few thousand cells. A typical protocol uses 0.5–1% low-melting-point agarose, lysis at 4°C for 1 hour, and electrophoresis at 25 V for 20–30 minutes.

γ-H2AX staining

Phosphorylation of histone H2AX at serine 139 (γ-H2AX) is an early response to DSBs. The kinase ATM phosphorylates H2AX within minutes of break formation, and the modification spreads over megabase regions flanking the break. γ-H2AX can be detected by immunofluorescence with a specific antibody, and the number of foci per nucleus correlates with the number of DSBs. This assay is quantitative and can be performed on fixed cells or tissue sections. It is widely used to measure radiation-induced damage, assess the efficacy of DNA-damaging chemotherapies, and evaluate repair kinetics.

Mutation reporter assays

Mutation reporter assays measure the frequency and spectrum of mutations induced by DNA damage. The HPRT (hypoxanthine-guanine phosphoribosyltransferase) assay uses cultured cells: mutations that inactivate HPRT confer resistance to 6-thioguanine, allowing mutant cells to be selected and counted. The lacI or lacZ transgene assays, used in transgenic rodents, allow mutations to be recovered from any tissue by phage packaging and screening in E. coli. These assays provide quantitative mutation frequencies and can reveal the mutational signature of specific damaging agents.

Clinical Implications and Cancer Prevention

Understanding DNA damage and repair has direct clinical applications in cancer risk assessment, prevention, and treatment.

Chemoprevention

Chemoprevention aims to reduce cancer incidence by preventing DNA damage or enhancing its repair. Antioxidants like N-acetylcysteine scavenge ROS and reduce oxidative damage, though clinical trials have shown mixed results. More targeted approaches include inhibitors of specific carcinogen activation, such as oltipraz, which induces phase II detoxifying enzymes and reduces aflatoxin-DNA adducts in humans. Aspirin reduces colorectal cancer risk, possibly by reducing inflammation-associated oxidative damage. The success of these agents depends on the balance between damage prevention and the potential for unintended effects on normal physiology.

Targeted therapies

The dependence of cancer cells on specific repair pathways creates therapeutic opportunities. PARP inhibitors (olaparib, niraparib) are effective in BRCA1/2-mutant tumors because these cells already lack HR; inhibiting PARP, which is involved in single-strand break repair, causes replication forks to collapse into DSBs that cannot be repaired by HR. This synthetic lethality is a paradigm for targeting repair defects.

DNA-damaging chemotherapies—cisplatin, temozolomide, doxorubicin—remain mainstays of treatment. Their efficacy depends on overwhelming the repair capacity of cancer cells. Resistance often arises through upregulation of repair pathways, such as increased expression of MGMT (O⁶-methylguanine-DNA methyltransferase) in glioblastoma, which directly reverses temozolomide-induced lesions. Combining DNA-damaging agents with inhibitors of specific repair pathways is an active area of investigation.

Common Pitfalls and Misconceptions

Students frequently misunderstand several aspects of DNA damage and cancer. Clarifying these points is essential for accurate conceptualization.

DNA damage vs. mutation

DNA damage and mutation are not synonymous. Damage is a chemical alteration that can be repaired; mutation is a permanent sequence change. Damage becomes mutation only when it is replicated or when repair is erroneous. This distinction matters because damage is transient and potentially reversible, whereas mutations are heritable. When discussing cancer causation, it is the mutations that drive tumorigenesis, not the damage itself.

All mutations are not carcinogenic

The vast majority of mutations are neutral or deleterious to the cell. Only mutations in specific genes—oncogenes, tumor suppressors, DNA repair genes—contribute to cancer. A cell with thousands of random mutations may still be phenotypically normal if none affect critical pathways. Moreover, most mutations are passenger mutations that do not confer a growth advantage; only driver mutations are selected during tumor evolution. The Molecular Basis of Cancer and Molecular Mechanism of Cancer are defined by these driver events, not by mutation burden alone.

Another misconception is that DNA damage always causes cancer. In fact, most damage is repaired, and most cells that sustain damage undergo apoptosis or senescence. Cancer arises only when damage escapes repair, the cell survives, and the resulting mutations confer a selective advantage. The Biology of Cancer involves multiple steps—initiation, promotion, progression—and DNA damage contributes primarily to initiation.

Summary and Key Takeaways

DNA damage is an unavoidable consequence of cellular life, arising from both endogenous metabolism and environmental exposures. The cell possesses multiple, overlapping repair pathways that recognize and correct specific classes of lesions. When repair fails, damage becomes mutation, and mutations in critical genes drive cancer development. The evidence linking DNA damage to cancer is overwhelming, from cancer-prone repair syndromes to carcinogen epidemiology to animal models. Understanding these mechanisms has direct clinical implications for cancer prevention and therapy.

Frequently Asked Questions

Can DNA damage cause cancer?

Yes. DNA damage is the initiating event in most cancers. When damage escapes repair and becomes fixed as a mutation in a gene that controls cell growth or survival, it can contribute to tumorigenesis. The causal link is supported by the fact that all known carcinogens damage DNA, and inherited defects in DNA repair pathways dramatically increase cancer risk.

How does DNA damage cause cancer?

DNA damage causes cancer through a multi-step process. First, a lesion must escape repair. During replication, error-prone translesion synthesis may insert an incorrect nucleotide opposite the lesion, creating a mutation. If this mutation occurs in an oncogene (activating it) or a tumor suppressor (inactivating it), the cell gains a growth advantage. Over time, additional mutations accumulate, eventually producing a fully malignant tumor.

Why does DNA damage cause cancer?

DNA damage causes cancer because it is the source of the mutations that drive tumorigenesis. Cancer is a genetic disease: it arises from alterations in genes that regulate proliferation, apoptosis, and genome stability. DNA damage, when unrepaired or misrepaired, generates these alterations. The reason damage is dangerous is that the genome is the repository of all hereditary information, and its integrity is essential for normal cellular function.

What types of DNA damage are most likely to cause cancer?

Double-strand breaks are the most dangerous because they can cause chromosomal rearrangements and large-scale deletions. However, the mutagenic potential of a lesion depends on its ability to miscode during replication. O⁶-methylguanine and 8-oxoguanine are highly mutagenic because they pair with incorrect bases. Bulky adducts and crosslinks are also carcinogenic because they block replication and can trigger error-prone bypass.

Can DNA damage be repaired?

Yes. Cells have multiple repair pathways: base excision repair for small base lesions, nucleotide excision repair for bulky adducts, mismatch repair for replication errors, and non-homologous end joining and homologous recombination for double-strand breaks. These pathways are highly efficient, but they are not perfect. Some damage escapes repair, and some repair events are themselves error-prone.

Is all DNA damage carcinogenic?

No. Most DNA damage is repaired without consequence, and most mutations that do arise are harmless. Carcinogenic damage is specifically that which produces mutations in cancer driver genes. Furthermore, many damaged cells undergo apoptosis or senescence, eliminating them before they can contribute to cancer. Cancer arises only when damage leads to mutations that confer a growth advantage and the cell escapes normal growth control.

How do scientists study DNA damage and cancer?

Scientists study DNA damage using biochemical assays (e.g., comet assay, γ-H2AX staining) to detect lesions, genetic approaches (e.g., mutation reporter assays) to measure mutagenesis, and animal models to test causation. Epidemiological studies of carcinogen exposure and genetic studies of cancer-prone syndromes provide human evidence. Together, these approaches have established the causal link between DNA damage and cancer and continue to inform prevention and therapy.

Key Takeaways

DNA damage is a chemical alteration to DNA; a mutation is a permanent sequence change that arises when damage is replicated or misrepaired.
Endogenous damage from ROS, hydrolysis, and replication errors is more frequent than exogenous damage from radiation and chemicals.
Five major repair pathways—BER, NER, MMR, NHEJ, and HR—handle distinct classes of lesions; defects in each predispose to specific cancers.
Unrepaired damage causes point mutations, frameshifts, and chromosomal aberrations that activate oncogenes or inactivate tumor suppressors.
Evidence from cancer-prone syndromes, carcinogen epidemiology, and animal models firmly establishes that DNA damage causes cancer.
Understanding DNA damage and repair has enabled targeted therapies such as PARP inhibitors for BRCA-mutant tumors.
Most DNA damage is repaired, and most mutations are harmless; cancer arises only from mutations in critical genes that confer a growth advantage.